pancreatic cancer liver metastasis
Conditions
Interventions
multi-mode thermal ablation combined with intravenous anti-PD-1 and chemotherapy:1. multi-mode thermal ablation
2. Camrelizumab 200 mg IV D1 + Gemcitabine 1000mg/m2 IV + albumin-bound paclitaxel125mg/
for 6 circles.
intravenous anti-PD-1 and chemotherapy:Camrelizumab 200 mg IV D1 + Gemcitabine 1000mg/m2 IV + albumin-bound paclitaxel125mg/m2 IV D1.8 Q3W
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Ages 18-70 years. Can be male or female; 2. Histologically confirmed pancreatic cancer with liver metastasis and no extrahepatic metastasis; 3. Measurable liver metastasis in CT or MRI, can be punctured safely; 4. Less than 3 lesions per half liver and less than 3 cm each; 5. ECOG score =2, expected survival more than 3 month.
Exclusion criteria
Exclusion criteria: 1. Child_Pugh level C with serious jaundice, especially obstructive jaundice; 2. Excessive tumor volume , or ablation range up to one-third of liver volume; 3. Expected survival less than 3 month; 4. Severe disorders of the heart, lung, liver, or kidney function, irreversible coagulation disorder; 5. Other uncontrolled diseases, including hypertension or diabetes, active infection, mental illness, or a social condition that may affect the subject’s compliance; 6. Intractable ascites, pleural effusion, or cachexia; 7. Pregnant or lactating women; 8. Other factors that researchers think not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;severe adverse event rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;objective response rate;disease control rate; | — |
Countries
China
Contacts
Public ContactLong Jiang
Shanghai General Hospital
Outcome results
None listed